

Eleonora Molinaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7665613/publications.pdf>

Version: 2024-02-01

30
papers

841
citations

567144

15
h-index

526166

27
g-index

30
all docs

30
docs citations

30
times ranked

940
citing authors

#	ARTICLE	IF	CITATIONS
1	Bilateral testicular metastases of medullary thyroid carcinoma in an adult male with multiple endocrine neoplasia 2A syndrome: case report and review of literature. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	1
2	Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors. <i>Thyroid</i> , 2021, 31, 1050-1055.	2.4	11
3	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 224-232.	2.4	30
4	Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. <i>Endocrine</i> , 2021, 72, 332-339.	1.1	10
5	Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3117.	1.8	36
6	Tall cell percentage alone in PTC without aggressive features should not guide patientsâ€™ clinical management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4109-e4117.	1.8	13
7	MANAGEMENT OF ENDOCRINE DISEASE: Papillary thyroid microcarcinoma: toward an active surveillance strategy. <i>European Journal of Endocrinology</i> , 2021, 185, R23-R34.	1.9	18
8	Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4068.	1.0	7
9	Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2021, 10, 399-407.	1.2	19
10	Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1124-e1134.	1.8	21
11	Response to Letter to the Editor: "Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2690-e2691.	1.8	0
12	Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?. <i>International Journal of Cancer</i> , 2020, 147, 2838-2846.	2.3	15
13	MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
14	Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-4.	0.2	4
15	Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2520-2526.	1.8	15
16	The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy. <i>Frontiers in Oncology</i> , 2019, 9, 1390.	1.3	3
17	Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan. <i>European Thyroid Journal</i> , 2019, 8, 90-95.	1.2	9
18	Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment. <i>Frontiers in Endocrinology</i> , 2018, 9, 590.	1.5	5

#	ARTICLE	IF	CITATIONS
19	Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without ¹³¹ I Ablation. <i>Thyroid</i> , 2018, 28, 871-879.	2.4	35
20	SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i388-i389.	0.4	1
21	Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 207-214.	1.2	0
22	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 319-334.	2.2	26
23	Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. <i>Endocrine-Related Cancer</i> , 2016, 23, R185-R205.	1.6	154
24	“Incidental” and “non-incidental” thyroid papillary microcarcinomas are two different entities. <i>European Journal of Endocrinology</i> , 2016, 174, 813-820.	1.9	17
25	Twenty years of lesson learning: how does the <i>RET</i> genetic screening test impact the clinical management of medullary thyroid cancer?. <i>Clinical Endocrinology</i> , 2015, 82, 892-899.	1.2	46
26	How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 331-344.	1.2	16
27	Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity ¹³¹ I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2693-2700.	1.8	61
28	Mild Decreases in White Blood Cell and Platelet Counts Are Present One Year After Radioactive Iodine Remnant Ablation. <i>Thyroid</i> , 2009, 19, 1035-1041.	2.4	41
29	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5686-5690.	1.8	167
30	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5686-5690.	1.8	60